Theravance Biopharma TBPH Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Yupelri Monotherapy | $94.74M+1.5% | $93.31M+1.5% | $91.95M+3.6% | $88.74M+4.9% | $84.61M+1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Theravance Biopharma break its business down?
- Theravance Biopharma (TBPH) reports revenue by product across 2 parts — Licensing And Milestone and Yupelri Monotherapy. Each is extracted from the segment footnotes and tracked over time.
- Where does Theravance Biopharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Theravance Biopharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
